Recently, PCSK9 inhibitors (anti-PCSK9 antibodies and PCSK9 translation inhibitors) have been reported to suppress the growth of APC/KRAS-mutant CRC and exert synergistic antitumor effects with simvastatin 60. Here, KRAS is linked to colorectal carcinoma.